Sean M. Post, Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Sean M. Post
Sean Post, M.D., is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Post received his Ph.D. in Molecular Medicine from the University of Texas Health Science Center at San Antonio in 2003. Dr. Post trained as a postdoctoral fellow in Department of Genetics at the MD Anderson Cancer Center under the tutelage of Dr. Gigi Lozano. In 2011, Dr. Post was appointed as a Tenure-Track faculty member in the Department of Leukemia. Dr. Post’s research is focused on identifying and understanding how novel genetic alterations impact cancer progression. His laboratory’s long-term objectives are develop personalized treatment strategies for patients with hematologic malignancies.
Present Title & Affiliation
Primary Appointment
Associate Professor, Leukemia, MD Anderson Cancer Center, Houston, TX
Associate Professor, Genetics, MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Leukemia, MD Anderson Cancer Center, Houston, TX
Associate Professor, Genetics, MD Anderson Cancer Center, Houston, TX
Member of Faculty, MD Anderson Cancer Center, Houston, TX
Research Interests
Identifying mechanisms critical to the development and sustentation of cancers is necessary for developing targeted therapies. To this end, we have uncovered novel mechanisms in the p53 pathway, tyrosine receptor kinase signaling pathways, and discovered the dual oncogenic and tumor suppressive functions of the RNA binding protein hnRNP K (heterogeneous nuclear ribonucleoprotein K). Through proof-of-concept studies, we have demonstrated that these genetic alterations offer therapeutic vulnerabilities that are amenable to indirect inhibition and we are now developing pre-clinical therapeutic strategies and novel small molecules to directly inhibit these proteins.
1. Identification of hnRNP K’s dual tumorsuppressive and oncogenic activities
Oncogenic Role of hnRNP K:
My laboratory has worked to determine how expression changes in hnRNP K impact tumor formation. To evaluate the oncogenic activity of hnRNP K, we initially used clinical samples isolated from patients with de novo AML and DLBCL. These studies revealed that overexpression of hnRNP K associates with poor clinical outcomes and treatment failures. To directly examine its role in tumorigenesis, we generated multiple mouse models to examine hnRNP K’s effect on both lymphoid and myeloid malignancies. We generated a novel B-cell specific transgenic mouse model (Eμ-Hnrnpk), and determined that hnRNP K is in fact an oncogene when overexpressed and that this overexpression facilitates malignant phenotypes through activation of the c-Myc pathway. Large scale ‘-omic’ studies, targeted molecular experiments, and pharmacologic studies revealed that hnRNP K has a significant role in protein translation and that the effects of its overexpression is amenable to therapeutic intervention (Gallardo and Malaney, JNCI 2020 and Malaney, Front Immunol 2021).
To understand how altered hnRNP K expression impacts myeloid biology, we again used large scale unbiased analyses. Here, we observed poor clinical outcomes in AML patients with increased hnRNP K expression. We next generated tissue specific Hnrnpk transgenic (Hnrnpk-Tg) mice and hnRNP K transplantation models that overexpress hnRNP K in the bone marrow compartment. Like the B-cell specific Hnrnpk-transgenic mice, Hnrnpk-Tg mice also developed a highly penetrant cancer phenotype, further indicating hnRNP K acts as an oncoprotein. In addition to changes in c-Myc, changes in hnRNP K expression directly impacted the expression of RUNX1 isoforms (Aitken, NAR Cancer, 2022 and ribosomal function (Aguilar-Garrido P, JCI, 2025) that drive myeloid malignancies.
Tumorsuppressive Role of hnRNP K:
Loss of the long arm of chromosome 9 (9q-) is commonly observed in a subset of AML patients, suggesting a tumor suppressor resides within this region. Genetic studies have mapped six candidate genes to a minimally deleted region of 9q21.32. However, the putative tumor suppressor had not been identified. Through data mining, we determined that hnRNP K was a likely candidate. Thus, to precisely determine its role in 9q-dependent AML, my laboratory generated a novel Hnrnpk haploinsufficient mouse model that mimics the genetic loss in some patients with AML. Haploinsufficient Hnrnpk mice have a significant reduction in survival, a highly penetrant malignant phenotype, and a significant expansion of the myeloid compartment. Mechanistically, our data indicated these hnRNP K-dependent phenotypes result from its inability to activate p53-dependent p21 expression and properly regulate expression of C/EBPα and β. These results indicate that hnRNP K is a critical regulator of the p53- and C/EBP- pathways and is in fact the tumor suppressor located at the 9q21.32 locus (Gallardo, Cancer Cell, 2015, Cell Cycle, 2016, Rahn K, Biochim Biophys Acta Gene Regul Mech, 2023).
Currently, we are pursuing two novel aspects related to the aforementioned overexpression and haploinsufficient studies. The first involves germline loss of function of HNRNPK. A rare HNRNPK-specific loss of function syndrome was recently described in children. This condition, called Au-Kline syndrome, results in devastating developmental and cognitive defects. Importantly, many of the clinical features are observed in our mouse model. Over the past several years, we have worked with Drs. Au and Kline to coordinate our effects to understand the pathways altered by HNRNPK loss. Dr. Au (University of Calgary) and I were awarded a rare disease grant (RRDM) funded through Canadian Agencies. We are evaluating the hnRNP K-dependent molecular pathways related to development.
The second extension of hnRNP K related research involves direct therapeutic targeting. To accomplish this, we have used fluorescence anisotropy, SPR, CESTA, cellular proliferation assays, and functional readouts to identify 9 “lead compounds” (out of ~80,000) that have the ability to disrupt hnRNP K’s RNA binding functions at concentrations from 0.1-30µM. We are now working with chemists (UT-Austin, Dr. Dalby) and structural biologist (MDACC, Dr. Tainer) to develop more potent analogs. Parts of these studies have been funded through an NCI-R01, LLS-TRP, NIH-SPORE, and various private foundations. Further, we have begun initial steps to patent the use of these compounds.
2. Alterations in the p53 pathway
p53 is a well-know tumor suppressor. As such, its role in tumorigenesis has been extensively characterized. However, significant gaps remain in our understanding of proteins that regulate p53 activity and thus its responses to various treatments. Over the past several years, we have worked to examine genetic aspects that alter p53 function and predict for varied therapeutic responses. Using a mouse model of B-cell chronic lymphocytic leukemia (B-CLL), my laboratory examined how cytotoxic and non-cytotoxic agents impact B-CLL progression when the p53 pathway is ablated (Lee, Blood Can Jour 2016). These studies demonstrated that loss of wild type p53 is not therapeutically dependent. Further, we used animal models and large-scale proteomics to evaluate proteins, protein signatures, and pathways that can predict for therapeutic response (Quintas-Cardama, Leukemia 2017, Post, Oncotarget 2017, Ortiz, Oncogene 2018, and Hoff, Proteomics Clin Appl 2019).
To expand on these findings, my laboratory is currently developing strategies to induce synthetic lethalities when p53 is lost (17p-). These studies will therapeutically (and genetically) target essential genes lost in conjunction with 17p deletions. Given the dismal prognosis of these patients and the lack of treatment options, these studies may have a tremendous impact on clinical outcomes. Aspects related to this work are currently being considered for funding by the AML-p53-committee of the Break Through Cancer Foundation.
3. Alterations in receptor tyrosine kinase signaling pathways
Aberrant activation of signaling pathways are a common feature in many malignancies. In AML, receptor tyrosine kinases (RTKs) are often altered, resulting in proliferation and differentiation defects. Furthermore, altered expression of ligands that bind specific receptors also drive tumorigenesis (Ruvolo, BBAMCR 2018 and 2020). We have worked to identify novel alterations and therapeutic vulnerabilities when receptor tyrosine kinases are altered. While a significant amount of attention is paid to FLT3 mutations, other RTKs play significant roles in AML. Over the past several years, we have evaluated the role that AXL plays in AML progression and have investigated the effects of a pre-clinical agent. Using AML cell lines, primary samples, and PDX models, we have determined AXL’s role in proliferation and apoptosis. Most importantly, we have demonstrated the efficacy of an AXL/MERTK-specific inhibitor in AML (Ruvolo, 2017). This compound, Ono-7475, significantly impacted AML cells in vivo and in vitro and is now in clinical trial at MD Anderson.
We have expanding on this work by examining how relapse/refractory AML responds to Ono-7475 and venetoclax combinations. These studies have demonstrated that AXL inhibition, in combination with venetoclax, triggers apoptosis and inhibits translational programs without stimulating MCL-1 expression (Post, Haematolgica, 2022). Through further funding by Ono Pharmaceutical, we are currently exploring additional molecular mechanisms that drive AXL-mediated AML.
Clinical Interests
While not involved in direct patient care, my laboratory is directly involved in correlative and translational aspects of prior and ongoing clinical trials. Our current focus is understanding how activation of the ISR pathway 'primes' AML cells for death. This work (with HiberCell, protocol: 2023-1016) is ongoing. We have submitted a CPRIT clinical trial application for additional funding for a sponsored trial.
Education & Training
Degree-Granting Education
| 2003 | University of Texas Health Science Center at San Antonio, San Antonio, Texas, US, Molecular Medicine, Ph.D |
| 1996 | University of Arkansas at Little Rock, Little Rock, Arkansas, US, Biology, BS |
Postgraduate Training
| 2004-2009 | Postgraduate Training, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2003-2004 | Postgraduate Training, Baylor College of Medicine, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Leukemia, MD Anderson Cancer Center, Houston, TX, 2011 - 2017
Instructor, Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011
Other Professional Positions
Sergeant, 1989 - 1997
Extramural Institutional Committee Activities
Chair, IACUC, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Research-Related Federal Developments Task Force, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Critical Care Medicine Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2026
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Vice Chair, IACUC, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Member, Genetics and Epigenetics Communications Committee (GSBS), The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, IACUC, The University of Texas MD Anderson Cancer Center, 2015 - Present
Faculty, Cancer Genetics and Epigenetics Program, The University of Texas MD Anderson Cancer Center, 2012 - Present
Editorial Activities
Editorial Board, Cancer Research, 2016 - 2019
Editorial Board, Journal of Genetic Syndrome & Gene Therapy, 2011 - Present
Honors & Awards
| 2020 - 2021 | Mentor Award, MD Anderson Cancer Center |
| 2011 - 2013 | MD Anderson Leukemia SPORE Career Development Award, The University of Texas MD Anderson Cancer Center |
| 2010 | 13th International p53 Workshop Outstanding Poster Award and Travel Award |
| 2009 | Genes and Development Program Retreat Award |
| 2009 | 5th International Mdm2 Workshop Outstanding Poster Award |
| 2006 - 2007 | Ruth Kristensen NIH Postdoctoral Fellowship |
| 2005 | Dodie P. Hawn Fellowship in Cancer Genetics, The University of Texas MD Anderson Cancer Center |
| 2002 - 2003 | Predoctoral Fellowship, Department of Defense |
| 2001 | 11th Annual Symposia on Cancer Research in San Antonio, Best Student Presentation, San Antonio Cancer Institute |
| 2001 | Department of Molecular Medicine/Institute Biotechnology Annual Retreat, Best Student Presentation, Institute Biotechnology |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. RNA binding proteins intersect development and tumorigenesis. Conference. Baylor College of Medicine. Houston, TX, US.
- 2019. The RNA binding protein hnRNPK is a driver of heme malignancies and a potential therapeutic target. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2010. Subtle modulation in the p53 pathway. Conference. MD Anderson Cancer Center, Center for Genetics and Genomic. Houston, TX, US.
- 2009. Mouse models of the p53 pathway. Conference. Texas Children’s Hospital, Hematology. Houston, TX, US.
- 2009. Mouse models of the p53 pathway. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2009. Mouse models of the p53 pathway. Conference. MD Anderson Cancer Center. Houston, TX, US.
- 2008. p53 pathway alterations in Cancer. Conference. MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2015. hnRNP K is a novel haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies. Conference. SOHO, US.
National Presentations
- 2025. Understanding the link between cancer and developmental biology. Conference. HNRNP-Related Neurodevelopment Disorders Scientific Symposium. Jacksonville, Florida, US.
- 2025. Connecting the Dots: Cellular Pathways Altered by HNRNPK. Conference. HNRNP-Related Neurodevelopment Disorders Scientific Symposium, US.
- 2024. Understanding how genetic alterations in HNRNPK impact human biology. Conference. HNRNP-Related Neurodevelopment Disorders Scientific Symposium. Seattle, Washington, US.
- 2024. HNRNPK alterations contribute to ribosomal defects in Au-Kline syndrome and hematopoietic malignancies. Conference. HNRNP-Related Neurodevelopment Disorders Scientific Symposium. Seattle, Washington, US.
- 2023. RNA binding proteins intersect development and tumorigenesis. Conference. HNRNP-Related Neurodevelopment Disorders Scientific Symposium, Columbia University, US.
- 2022. HNRNPK haploinsufficient Mice: A potential tool to understand Au-Kline Syndrome, HNRNP-Related Neurodevelopment Disorders Scientific Symposium. Conference. Columbia University, US.
- 2021. Harnessing Mechanistic Insights to Target the Oncogenic Functions of hnRNP K. Conference. FASEB, Hematological Malignancies, US.
- 2018. Unraveling the Mechanisms of a Dual Tumor Suppressor and Oncogene that Drives Hematologic Malignancies. Conference. Association of Clinical Scientists Annual Meeting. Houston, TX, US.
- 2016. hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation. Conference. American Society of Hematology 58th Annual Meeting. San Diego, CA, US.
- 2015. hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. Conference. American Society of Hematology 57th Annual Meeting. Orlando, FL, US.
- 2015. hnRNP K Drives c-Myc-Dependent Malignancies and Represent a Novel Therapeutic Opportunity for Hematologic Malignancies. Conference. American Society of Hematology 57th Annual Meeting. Orlando, FL, US.
- 2014. hnRNP K: A Tumor Suppressor or Oncogene?. Conference. American Society of Hematology 56th Annual Meeting. San Francisco, CA, US.
- 2013. hnRNP K: a novel regulator of hematopoiesis and a potential predictive biomarker in Acute Myeloid Leukemia. Conference. American Society of Hematology 55th Annual Meeting. New Orleans, LA, US.
- 2012. 774 hnRNP K: A Putative Regulator of Leukemogenesis and the p53 Pathway. Oral presentation. Conference. American Society of Hematology 54th Annual Meeting. Atlanta, GA, US.
- 2012. hnRNP K: A Putative Regulator of Leukemogenesis and the p53 Pathway (oral presentation). Conference. American Society of Hematology 54th Annual Meeting. Atlanta, GA, US.
International Presentations
- 2019. hnRNP K levels predict for poor clinical responses in DLBCL and represent a novel therapeutic target. Conference. European Hematology Association 24th Annual Congress. Amsterdam, NL.
- 2019. hnRNP K overexpression drives myeloid malignancy via interaction with RUNX1, Keystone Symposia on RNA-Protein Interactions/Long Non-Coding RNAs. Conference. Whistler. British Columbia, CA.
- 2016. Identification of Novel Regulators and Therapeutic Targets in Hematologic Malignancies 21st World Congress on Advances in Oncology and 19th International Symposium on Molecular Medicine. Invited. 21st World Congress on Advances in Oncology and 19th International Symposium on Molecular Medicine. Athens, GR.
- 2016. HNRNP K: AN ONCOGENE AND TUMOR SUPPRESSOR, TWO DISCRETE PATHS TO AML THROUGH ONE GENE. Conference. European Hematology Association 21st Annual Congress. Copenhagen, DK.
- 2014. Identification of a Potentially Novel Tumor Suppresor in AML. Conference. European Hematology Association 19th Annual Congress. Milan, IT.
Formal Peers
- 2021. Understanding the mechanisms and developing novel therapies for a high-risk DLBCL population. Invited, US.
- 2020. Characterizing the Role of an RNA Binding Protein in Hematologic Malignancies. Invited, US.
- 2016. Developing Personalized Therapies for a High-Risk Patient Population with Acute Myeloid Leukemia. Invited. Madrid, ES.
- 2014. Using targeted mouse models as a preclinical platform for drug discoveries. Invited. Basel, CH.
- 2014. Predictive models in leukemic development and therapeutic responses. Invited. Ulm, DE.
- 2012. Examining the impact of altered p53 regulation in mice and men. Invited. Dayton, OH, US.
- 2011. Subtle changes in the p53 pathway impact tumorigenesis. Invited. Houston, TX, US.
- 2011. Subtle changes in the p53 pathway impact tumorigenesis. Invited. Philadelphia, PA, US.
- 2010. Subtle changes in the p53 pathway impact tumorigenesis. Invited. Philadelphia, PA, US.
- 2010. Subtle changes in the p53 pathway impact tumorigenesis. Invited. Salt Lake City, UT, US.
- 2010. Subtle changes in the p53 pathway impact tumorigenesis. Invited. Columbia, SC, US.
- 2010. Subtle changes in the p53 pathway impact tumorigenesis. Invited. San Antonio, TX, US.
- 2010. Subtle changes in the p53 pathway impact tumorigenesis. Invited. Houston, TX, US.
- 2010. Mouse models of the p53 pathway. Invited. Piedras, PR, PR.
- 2010. Mouse models of the p53 pathway. Invited. Piedras, PR, PR.
- 2001. Cell Signaling in Cancer. Invited. San Antonio, TX, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Epithelial mechanisms of inducible antiviral resistance against AML-associated pneumonia |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 1R01HL187192-01 |
| Date: | 2025 - 2028 |
| Title: | Exploiting synthetic lethalities between HNRNPK loss and ribosomal dysfunction in del9q AML |
| Funding Source: | CPRIT |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | 9q deletions and HNRNPK mutations uncover novel therapeutic opportunities to induce synthetic lethality and eradicate AML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA296622-01 |
| Date: | 2024 - 2026 |
| Title: | A Phase I study of HC-7366 Monotherapy and in Combination with Azacitidine Venetoclax in Acute Myeloid Leukemia |
| Funding Source: | other |
| Role: | Co-PI |
| Date: | 2024 - 2027 |
| Title: | Investigating the Impact of Interferon Gamma Signaling on Therapeutic Resistance in Acute Myeloid Leukemia |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Date: | 2024 |
| Title: | Exploiting Synthetic Lethalities between HNRNPK Loss and Ribosomal Dysfunction in del9q AML |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Exploiting hnRNP K-mediated Translational Defects to eradicate Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 2R01CA207204-06A1 |
| Date: | 2023 - 2026 |
| Title: | Understanding how an RNA binding protein influences cancer progression and therapeutic responses |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | FP00014073_Res1 |
| Date: | 2022 - 2024 |
| Title: | Understanding the Combinational Effect of Hydroxyurea and Cd C7 Inhibition in Targeting Acute Myeloid Leukemia |
| Funding Source: | Lin BioScience |
| Role: | Co-PI |
| ID: | RCTS#61219 |
| Date: | 2022 - 2023 |
| Title: | Understanding the combinational effect of hydroxyurea and Cd acute myeloid leukemia C7 inhibition in targeting acute myeloid leukemia |
| Funding Source: | Lin BioSciences |
| Role: | Co-PI |
| ID: | RCTS#61219 |
| Date: | 2022 - 2024 |
| Title: | CRISPR/Cas9 screen to identify synthetic lethal targets in del9qAML |
| Funding Source: | NIH/NCI (Leukemia SPORE) |
| Role: | PI |
| ID: | P50 CA100632-20-20 |
| Date: | 2022 - 2023 |
| Title: | CRISPR/Cas9 screen to identify synthetic lethal targets in del9qAML |
| Funding Source: | NIH/NCI (Leukemia SPORE Matching Funds) |
| Role: | PI |
| ID: | P50 CA100632-20 |
| Date: | 2022 - 2025 |
| Title: | Therapeutic targeting of an RNA binding protein that drives hematologic malignancies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP220336 |
| Date: | 2022 - 2024 |
| Title: | Identification and evaluation of critical metabolic and ribogenesis defects driven by reduced hnRNP K expression |
| Funding Source: | IRG (Institutional Research Grant) |
| Role: | PI |
| ID: | RCTS#00060675 |
| Date: | 2021 - 2023 |
| Title: | Elucidation of the role of metals in AML biology for the development of chelators as therapeutic agents |
| Funding Source: | Pleco Therapeutics |
| Role: | Co-PI |
| Date: | 2021 - 2023 |
| Title: | Characterization and optimization of a novel class of RNA Binding Protein Inhibitors |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| ID: | FP00013627 |
| Date: | 2021 - 2026 |
| Title: | Identifying and exploiting therapeutic vulnerabilities in hnRNP K-dependent malignancies |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | Identifying and exploiting therapeutic v |
| Date: | 2021 - 2023 |
| Title: | Identification and evaluation of critical metabolic and ribogenesis defects driven by reduced hnRNP K expression |
| Funding Source: | NIH/NHLBI |
| Role: | PI |
| ID: | 13321147 |
| Date: | 2021 - 2022 |
| Title: | Epigenetics SPORE - Developmental Research Program |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Identification and evaluation of critical metabolic and ribogenesis defects driven by hnRNP K haploinsufficiency |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21 |
| Date: | 2020 - 2022 |
| Title: | Targeting the oncogenic functions of hnRNP K in high-risk lymphomas |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | Co-PI |
| Date: | 2020 - 2021 |
| Title: | Developing small molecule analogs that target hnRNP K-dependent malignancies |
| Funding Source: | MD Anderson Cancer Center Institutional Research Grant |
| Role: | PI |
| ID: | RCTS#00058089 |
| Date: | 2019 - 2020 |
| Title: | Development of novel small molecules that specifically target hnRNP K-dependent malignancies |
| Funding Source: | UTMDACC Leukemia SPORE Development Award |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | Study of Ixazomib and Rituximab in Bruton Tyrosine Kinase Inhibitor Resistant Mantle Cell Lymphoma |
| Funding Source: | Takeda Alliance/Clinical Studies |
| Role: | Co-PI |
| Date: | 2018 - 2020 |
| Title: | Studies to investigate efficacy of AXL inhibitor ONO-7475 for AML and ALL therapies |
| Funding Source: | Ono Pharmaceuticals |
| Role: | Co-I |
| ID: | 55982 |
| Date: | 2018 - 2023 |
| Title: | Understanding the mechanisms and developing novel therapies for a high-risk DLBCL population |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Development of personalized therapies and novel compounds for hnRNP K/c-Myc-driven Leukemias |
| Funding Source: | Leukemia Texas |
| Role: | PI |
| ID: | FP00005744COR |
| Date: | 2018 - 2023 |
| Title: | Targeting Bone Marrow Fibrosis in Primary Myelofibrosis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2018 - 2021 |
| Title: | Targeting AXL with ONO-7475 to reverse drug resistance in FLT3 ITD AML |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Collaborator |
| Date: | 2018 - 2020 |
| Title: | hnRNP K: a putative driver of high risk DLBCL |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Mentor |
| Date: | 2018 - 2019 |
| Title: | Novel therapeutic approaches to treat high-risk DLBCL |
| Funding Source: | ELSA U PARDEE FOUNDATION |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Understanding the mechanisms and developing novel therapies for a high-risk DLBCL population |
| Funding Source: | Ladies Leukemia League |
| Role: | Principal Investigator-MDACC |
| Date: | 2018 - 2020 |
| Title: | ONO-9330547 as a novel strategy in target leukemia cells within their BM Microenvironment develop novel FLT3-ITD transplantation models and evaluate the efficiency of experimental therapies for these mutations |
| Funding Source: | Ono Pharmaceutical |
| Role: | PI |
| ID: | ONO-9330547 |
| Date: | 2017 - 2018 |
| Title: | Identification and development of novel compounds for hnRNP K/c-Myc-driven leukemias |
| Funding Source: | UTMDACC Leukemia SPORE Development Award |
| Role: | PI |
| Date: | 2017 - 2022 |
| Title: | Strategic Alliance Agreement (Daiichi Sankyo and Plexxikon) |
| Funding Source: | Daiichi Sankyo |
| Role: | Co-I |
| ID: | 54920 |
| Date: | 2017 - 2019 |
| Title: | Preclinical Testing of Galectin-3C for Multiple Myeloma |
| Funding Source: | Kiromic Pharma |
| Role: | Co-PI |
| Date: | 2016 - 2018 |
| Title: | Galectin 3 inhibition as a novel strategy for targeting leukemic cells with their BM microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2016 - 2017 |
| Title: | Using a Novel Combinational Approach to Target a High-Risk AML Patient Population |
| Funding Source: | The University of Texas MD Anderson Cancer Center MDS/AML Moon Shot Program |
| Role: | Project Leader |
| Date: | 2016 - 2023 |
| Title: | Principal Investigator, 40%, Personalized therapy for AML patients with a newly identified genetic alteration |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA207204 |
| Date: | 2016 - 2017 |
| Title: | ONO-9330547 as a novel strategy for targeting acumte myeloid leukemia cells within the bone marrow microenvironment |
| Funding Source: | Ono Pharmaceutical |
| Role: | Co-I |
| Date: | 2016 - 2017 |
| Title: | Galectin 3 inhibition using Kiromic Galectin Inhibitors as a novel strategy for targeting leukemic cells with their BM microenvironment |
| Funding Source: | Kiromics Inc |
| Role: | Co-PI |
| Date: | 2016 - 2018 |
| Title: | Examining Targeted Therapies for a Novel High Frequency Alteration in AML |
| Funding Source: | IRG |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | Examining a Novel Combinational Approach in Treating Mutant p53-dependent CLL |
| Funding Source: | CLLGlobal Research Foundation |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Individualizing AML treatment strategies with BET bromodomain inhibitors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP160465 |
| Date: | 2015 - 2018 |
| Title: | Examining Targeted Therapies for a Novel Alteration in Acute Myeloid Leukemia |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2015 - 2016 |
| Title: | Pilot Proposal: Using bromodomain-based therapies to target novel drivers of acute myeloid leukemia |
| Funding Source: | MD Anderson Cancer Center MDS/AML Moon Shot Program |
| Role: | Project Leader |
| Date: | 2015 - 2018 |
| Title: | CA140306: A Dual Role for hnRNP K: A Tumor Suppressor and an Oncogene |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | T-cell activating immunotherapy for indolent B-cell malignancies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP150316 |
| Date: | 2015 - 2017 |
| Title: | Therapeutically targeting a novel regulator of acute myeloid leukemia |
| Funding Source: | Gilead |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | Aberrant hnRNP K expression and cancer: Walking a tightrope |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| Date: | 2014 - 2015 |
| Title: | Pharmacological evaluation of CBP as a target for anti-cancer therapy |
| Funding Source: | Center for Cancer Epigenetics |
| Role: | Co-I |
| Date: | 2014 - 2015 |
| Title: | Understanding aberrant hnRNP K expression in myeloid homeostasis and AML |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| Date: | 2014 - 2018 |
| Title: | Aberrant hnRNP K expression and cancer: Walking a tightrope |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | ASH Scholar Award in Basic/Translational Research for Junior Faculty: hnRNP K: a novel leukemia biomarker and regulator of hematopoietic differentiation |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| ID: | 01 |
| Date: | 2014 - 2016 |
| Title: | Aberrant hnRNP K expression and cancer: Walking the tightrope |
| Funding Source: | Sidney Kimmel Foundation |
| Role: | PI |
| Date: | 2014 - 2015 |
| Title: | Aberrant hnRNP K expression and leukemia: Walking a tightrope |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | T-cell activating immunotherapy for B-cell malignancies |
| Funding Source: | SWOG/Hope Foundation |
| Role: | Co-PI |
| Date: | 2014 - 2016 |
| Title: | R. Lee Clark Fellows Award |
| Funding Source: | University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2013 - 2014 |
| Title: | Neoplastic Fibrocytes Induce Bone marrow Fibrosis in Primary Myelofibrosis |
| Funding Source: | MPN Research Foundation |
| Role: | Co-I |
| ID: | 01 |
| Date: | 2013 - 2018 |
| Title: | hnRNP K:a novel biomarker leukemia and regulator of hematopoietic differentiation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | PA12-0221 |
| Date: | 2013 - 2017 |
| Title: | Evaluating the impact of aberrant hnRNP K expression on the p53 pathway and AML progression |
| Funding Source: | American Cancer Society (ACS) |
| Role: | PI |
| ID: | 01 |
| Date: | 2013 - 2016 |
| Title: | ASH Scholar in Basic/Translational Research Junior Faculty: Evaluating the impact of aberrant hnRNP K expression on the p53 pathway and AML progression |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | PI |
| ID: | 01 |
| Date: | 2013 - 2016 |
| Title: | Identification of Novel Prognostic Factors in Hematological Malignancies |
| Funding Source: | Searle |
| Role: | PI |
| ID: | Searle Scholar Program |
| Date: | 2013 - 2016 |
| Title: | Understanding and overcoming mutant p53 mediated resistance in CLL05 |
| Funding Source: | CLL Global Research Foundation |
| Role: | PI |
| Date: | 2013 - 2018 |
| Title: | New Approaches to the Biology and Treatment of MDS Project 3: Innate Immunity Alterations in MDS |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | 1 P01 HL117793-01 |
| Date: | 2013 - 2017 |
| Title: | Nucleophosmin Mutations Disrupt Normal p53 Activities In AML |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Co-I |
| ID: | 01 |
| Date: | 2012 - 2017 |
| Title: | Evaluating the impact of a putative regulator of the p53 pathway |
| Funding Source: | Rita Allen Foundation |
| Role: | PI |
| ID: | 01 |
| Date: | 2012 - 2014 |
| Title: | Evaluation of biomarkers for CLL progression in the p53 pathway: a genetic approach in mice and man |
| Funding Source: | Lymphoma Research Foundation |
| Role: | PI |
| ID: | 01 |
| Date: | 2012 - 2014 |
| Title: | Evaluating the impact of hnRNP K expression on the p53 pathway and in tumorigenesis |
| Funding Source: | Sidney Kimmel Foundation |
| Role: | PI |
| ID: | 01 |
| Date: | 2012 - 2013 |
| Title: | A regulator of p53 function influences tumor formation and leukemogenesis |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | 01 |
| Date: | 2012 - 2013 |
| Title: | CDP: Evaluating the impact of aberrant hnRNP K expression on the p53 pathway and AML |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5 P50 CA100632-09 |
| Date: | 2011 - 2012 |
| Title: | Evaluating the Impact of Mdm2SNP309 in Colon Cancer |
| Funding Source: | Center for Genetics and Genomics |
| Role: | PI |
| ID: | 01 |
| Date: | 2011 - 2013 |
| Title: | The role of Mdm2SNP 309 in CLL |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5P50 CA100632-08 |
| Date: | 2006 - 2007 |
| Title: | A polymorphism in the Mdm2 promoter enhances cancer risk |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | F32 CA119616 |
| Date: | 2002 - 2004 |
| Title: | Phosphorylation of human Rad17 by ATR is required for cell cycle checkpoint activation |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | DAMD17-02-1-0588 |
| Title: | Identification of novel therapeutic targets of c-Myc in Acute Myeloid Leukemia |
| Funding Source: | Mike Hogg Fund |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- KasnerCorresponding Author MT, Courtenay-Luck N, DiNardo C, Post SM, Baratam P, Magrath GN, Nakamura T, Fujii A, Prados S, Honda N, Mcbride M, Edwards-Holmes P, Stuart R. Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study. Acta Haematol, 2025. PMID: 41385448.
- Aguilar-Garrido P, Velasco-Estevez M, Navarro-Aguadero MA, Otero-Sobrino A, Ibanez-Navarro M, Marugal MA, Hernandez-Sanchez M, Malaney P, Rodriguez A, Benitez O, Zhang X, Aitken MJ, Ortiz-Ruiz A, Megias D, Perez M, Mata G, Gomez J, Lafarga M, Dominguez O, Grana-Castro O, Caleiras E, Ximenez-Embun P, Isasa M, de Andres PJ, Rodriguez-Perales S, Torres-Ruiz R, Revilla E, Garcia-Martin RM, Azorin D, Zubicaray J, Sevilla J, Sirozh O, Lafarga V, Martinez-Lopez J, Post SM, Gallardo M. The tumor suppressor HNRNPK induces p53-dependent nucleolar stress to drive ribosomopathies. J Clin Invest 135(12):e183697, 2025. e-Pub 2025. PMID: 40338663.
- Rahn K, Abdallah AT, Gan L, Herbrich S, Sonntag R, Benitez O, Malaney P, Zhang X, Rodriguez AG, Brottem J, Marx G, Brümmendorf TH, Ostareck DH, Ostareck-Lederer A, Crysandt M, Post SM, Naarmann-de Vries IS. Insight into the mechanism of AML del(9q) progression: hnRNP K targets the myeloid master regulators CEBPA (C/EBPα) and SPI1 (PU.1). Biochim Biophys Acta Gene Regul Mech 1867(1):195004, 2024. e-Pub 2024. PMID: 38008244.
- Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
- Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res:OF1-OF18, 2024. PMID: 37285177.
- Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, Burks JK, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res 11(7):1011-1028, 2023. e-Pub 2023. PMID: 37163233.
- Aitken MJL, Malaney P, Zhang X, Herbrich SM, Chan L, Benitez O, Rodriguez AG, Ma H, Jacamo R, Duan R, Link TM, Kornblau SM, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing. NAR Cancer 4(4):zcac039, 2022. e-Pub 2022. PMID: 36518526.
- Malaney P, Benitez O, Zhang X, Post SM. Assessing the role of intrinsic disorder in RNA-binding protein function: hnRNP K as a case study. Methods 208:59-65, 2022. e-Pub 2022. PMID: 36334888.
- Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
- Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica 107(6):1311-1322, 2022. e-Pub 2022. PMID: 34732043.
- Manshouri T, Veletic I, Li P, Yin CC, Post SM, Verstovsek S, Estrov Z. GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis 13(5):481, 2022. e-Pub 2022. PMID: 35595725.
- Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, Daver N, Zha D, Konopleva M. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326171.
- Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Post SM, Andreeff M. LGALS1 acts as a pro-survival molecule in AML. Biochim Biophys Acta Mol Cell Res 1867(10):118785, 2020. e-Pub 2020. PMID: 32590026.
- Gallardo M, Malaney P, Aitken MJL, Zhang X, Link TM, Shah V, Alybayev S, Wu MH, Pageon LR, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton MC, Martinez-Lopez J, Bueso-Ramos C, Young KH, Post SM. Uncovering the role of hnRNP K, an RNA-binding protein, in B-cell lymphomas. J Natl Cancer Inst 112(1):95-106, 2020. e-Pub 2020. PMID: 31077320.
- Hoff FW, Hu CW, Qutub AA, Qiu Y, Hornbaker MJ, Bueso-Ramos C, Abbas HA, Post SM, ESJM DB, Kornblau SM. Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse. Proteomics Clin Appl 13(4):e1800133, 2019. e-Pub 2019. PMID: 30650251.
- Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):1-12, 2019. e-Pub 2019. PMID: 29741984.
- Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PLoS One 14(9):e0222912, 2019. e-Pub 2019. PMID: 31569199.
- Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865(7):959-969, 2018. e-Pub 2018. PMID: 29655803.
- Ortiz GJ, Li Y, Post SM, Pant V, Xiong S, Larsson CA, El-Naggar AK, Johnson DG, Lozano G. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene 37(3):332-340, 2018. e-Pub 2018. PMID: 28925402.
- Post SM, Kornblau SM, Quintás-Cardama A. p53 pathway dysfunction in AML: beyond TP53 mutations. Oncotarget 8(65):108288-108289, 2017. e-Pub 2017. PMID: 29312530.
- Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM. Anexelekto /MER Tyrosine Kinase inhibitor ONO-7475 growth arrests and kills FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Mutant Acute Myeloid Leukemia cells by diverse mechanisms. Haematologica 102(12):2048-2057, 2017. e-Pub 2017. PMID: 28912176.
- Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M. Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget 8(43):74378-74390, 2017. e-Pub 2017. PMID: 29088794.
- Quintás-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, Zhang N, Coombes K, Kornblau SM. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia 31(6):1296-1305, 2017. e-Pub 2017. PMID: 27885271.
- Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med 213(9):1723-40, 2016. e-Pub 2016. PMID: 27481130.
- Gallardo M, Hornbaker MJ, Zhang X, Hu P, Bueso-Ramos C, Post SM. Aberrant hnRNP K expression: All roads lead to cancer. Cell Cycle 15(12):1552-7, 2016. e-Pub 2016. PMID: 27049467.
- Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, Hornbaker MJ, Qi Y, Su X, Pageon LR, Quintas-Cardama A, Post SM. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J 10(6):434, 2016. e-Pub 2016. PMID: 27284738.
- Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies. Cancer Cell 28(4):486-99, 2015. e-Pub 2015. PMID: 26412324.
- Zhang X, Pageon L, Post SM. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer. Oncogene 34(33):4412-20, 2015. e-Pub 2015. PMID: 25435368.
- Quintás-Cardama A, Zhang N, Qiu YH, Post S, Creighton CJ, Cortes J, Coombes KR, Kornblau SM. Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(2):115-127.e15, 2015. e-Pub 2015. PMID: 25248926.
- Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, Lozano G, Barton MC. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 62(2):371-9, 2015. e-Pub 2015. PMID: 25281858.
- Chen J, Shin JH, Zhao R, Phan L, Wang H, Xue Y, Post SM, Ho Choi H, Chen JS, Wang E, Zhou Z, Tseng C, Gully C, Velazquez-Torres G, Fuentes-Mattei E, Yeung G, Qiao Y, Chou PC, Su CH, Hsieh YC, Hsu SL, Ohshiro K, Shaikenov T, Wang H, Yeung SC, Lee MH. CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun 5:5384, 2014. e-Pub 2014. PMID: 25395170.
- Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol 234(1):108-19, 2014. e-Pub 2014. PMID: 24890125.
- Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev 27(17):1857-67, 2013. e-Pub 2013. PMID: 23973961.
- Quintás-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J, Kornblau SM. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 118(21):5283-92, 2012. e-Pub 2012. PMID: 22517119.
- Post SM. Mouse models of sarcomas: critical tools in our understanding of the pathobiology. Clin Sarcoma Res 2(1):20, 2012. e-Pub 2012. PMID: 23036318.
- Lee HJ, Zhang X, Attie Y, Post SM. Knowing is Half the Battle in the Genetics of Acute Myelogenous Leukemia. Genetic Syndromes & Gene Therapy 112(3), 2012. e-Pub 2012.
- Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer Res 71(23):7168-75, 2011. e-Pub 2011. PMID: 21983037.
- Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcomas. J Pathol 222(2):124-8, 2010. e-Pub 2010. PMID: 20821751.
- Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcoms. Journal of Pathology. Journal of Pathology 222(2):124-8, 2010. e-Pub 2010.
- Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 18(3):220-230, 2010. e-Pub 2010. PMID: 20832750.
- Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res 70(18):7148-54, 2010. e-Pub 2010. PMID: 20736370.
- Xiong S, Pant V, Suh YA, Van Pelt C, Wang Y, Valentin-Vega Y, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing Mdm4. Cancer Research 70(18):7148-54, 2010. e-Pub 2010.
- Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One 5(5):e10813, 2010. e-Pub 2010. PMID: 20520810.
- Fang S, Krahe R, Lozano G, Han Y, Chen W, Bachinski LL, Post SM, Wilson C, Strong LC, Amos CI. The effect of Mdm2 and p53 codon72 polymorphisms on cancer risk in p53 germline mutation carriers. PLoS One 5(5), 2010. e-Pub 2010.
- Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 29(9):1260-9, 2010. e-Pub 2010. PMID: 19935700.
- Martinez LA, Goluszko E, H-Z C, Leone G, Post SM, Lozano G, Chen Z, Chauchereau A. E2F3a is a Mediator of DNA Damage Induced Apoptosis. Mol. Cell. Bio 30(2):524-36, 2010. e-Pub 2010.
- Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22(10):1337-44, 2008. e-Pub 2008. PMID: 18483220.
- Song W, Levin DS, Varkey J, Post SM, Bermudez VP, Hurwitz J, Tomkinson AE. A conserved physical and functional interaction between the cell cycle checkpoint clamp loader and DNA ligase I of eukaryotes. J. Biol. Chem 282(31):22721-30, 2007. e-Pub 2007.
- Post SM, Groenendijk M, Solaas K, Rensen PC, Princen HM. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol 24(4):768-74, 2004. e-Pub 2004. PMID: 14962946.
- Motycka TA, Bessho T, Post SM, Sung P, Tomkinson AE. Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52. J. Biol. Chem 279(14):13634-9, 2004. e-Pub 2004.
- Post SM, Lee EY. Detection of kinase and phosphatase activities. Methods Mol Biol 241:285-97, 2004. e-Pub 2004. PMID: 14970662.
- Post SM, Tomkinson AE, Lee EY. The human checkpoint Rad protein Rad17 is chromatin-associated throughout the cell cycle, localizes to DNA replication sites, and interacts with DNA polymerase epsilon. Nucleic Acids Res 31(19):5568-75, 2003. e-Pub 2003. PMID: 14500819.
- Post SM, Weng YC, Cimprich K, Chen LB, Xu Y, Lee E. Phosphorylation of serines 635 and 645 of human Rad17 is cell cycle regulated and is required for G1/S checkpoint activation in response to DNA damage. Proc Natl Acad Science 98(23):13102-13107, 2001. e-Pub 2001.
Invited Articles
- Post SM, Andreeff M, DiNardo C, Khoury JD, Ruvolo PP. TAM kinases as regulators of cell death. Biochim Biophys Acta Mol Cell Res 1868(6):118992, 2021. e-Pub 2021. PMID: 33647320.
- Malaney P, Velasco-Estevez M, Aguilar-Garrido P, Aitken MJL, Chan LE, Zhang X, Post SM, Gallardo M. The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies. Front Immunol 12(12:634584):634584, 2021. e-Pub 2021. PMID: 33912162.
- Aitken MJL, Lee HJ, Post SM. Emerging treatment options for patients with p53 pathway-deficient CLL. Therapeutic Advances in Hematology 10(2040620719891356), 2019. e-Pub 2019. PMID: 31839919.
- Post SM. One size doesn't fit all in Ph-like ALL. Blood 12(129):140-141, 2017. e-Pub 2017. PMID: 28082291.
- Lee HJ, Gallardo M, Zhang X, Quintas-Cardama A, Post SM. p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia. Blood 122(21):2885, 2013. e-Pub 2013.
Review Articles
- Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol 223(2):127-36, 2011. e-Pub 2011. PMID: 20957626.
- Post SM, Pant V, Abbas H, Quintás-Cardama A. Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma. Oncotarget 1(3):168-74, 2010. e-Pub 2010. PMID: 21301048.
- Post SM, Quintás-Cardama A. Closing in on the pathogenesis of the 5q- syndrome. Expert Rev Anticancer Ther 10(5):655-8, 2010. e-Pub 2010. PMID: 20469997.
Other Articles
- Post SM, Chan LE, Zhang X, Benitez O, Rahn K, Link T, Stephan C, Cho E, Dalby K, Malaney P Assay development and small molecule screens for inhibitors of an RNA binding protein in hematologic malignancies. Blood 140(1):4951, 2022.
Abstracts
- Rodriguez A, Benitez O, Brottom J, Manshouri T, Frattini M, Wang I, Maiti A, Post S. TARGETING DNA REPLICATION AND THE INTRA-S-PHASE CHECKPOINT FOR TREATMENT OF TP53-MUTATED AML. EHA Library, 2025.
- Sean P, Oscar B, Ashley R, Marisa A, Prerna M, Miguel G, Hussein A. Hnrnpk haploinsufficiency in del(9q) Acute Myeloid Leukemia reveals targetable vulnerabilities 146(1):5028, 2025.
- Maiti A, Post SM, DiNardo CD, Daver NG, Kadia TM, Pike A, Hwang H, Huang X, Andreeff M, Ravandi F, Choi J, Kim J, Nam K, Borthakur G. Phase 1 study of AXL/MER/CSF1R inhibitor Q702 with azacitidine and venetoclax for R/R AML 144(1), 2024.
- Post SM, Post SM, DiNardo CD, Daver NG, Kadia TM, Pike A, Hwang H, Huang X, Andreeff M, Ravanadi F, CHOI J, Ahn H, Kim J, Nam K, Borthakur G. Phase 1 study of AXL/MER/CSF1R inhibitor Q702 with azacitidine and venetoclax for R/R AML. Blood 144(1):5994, 2024.
- Post SM, Rodriguez AG, Benitez O, Brottem J, Wang I, Chang J, Frattini MG, Maiti A. Unraveling Novel Mechanisms for Targeting the Intra-S-Phase Checkpoint in p53-Mutated AML. Blood 142(1):1423, 2023.
- Post SM, Rhan K, Herbrich S, Benitez O, Rodriguez AG, Zhang X, Meier MR, Brottem J, Crysandt M, Malaney P, naarmann-Devries I. A potential link between hnRNP K and Cebpα: Implications for ribosomal dysfunction in AML. Blood 142(1):4119, 2023.
- Aguilar-Garrido P, Velasco M, Hernández Sánchez M, Navarro Aguadero MA, Malaney P, Aitken MJ, Zhang X, Young KH, Duan R, Hu P, Kornblau SM, Fernández A, Ortiz A, Otero-Sobrino A, de Andrés PJ, Megías D, Pérez M, Gómez J, Mata G, Martínez López J, Post SM, Gallardo M. RBPS DYSREGULATION CAUSE HYPER-NUCLEOLI AND RIBOSOME GAIN-OF-FUNCTION DRIVING BONE MARROW FAILURE. EHA Library 356969(S104), 2022. e-Pub 2022.
- Post SM. Assay development and small molecule screens for inhibitors of an RNA binding protein in hematologic malignancies. Blood 140(1):4951, 2022.
- Post SM, Malaney P, Chan L, Zhang X, Link T, Cho E, Cerda J, Aitken MJ, Sobieski M, Powell R, Nguyen N, Stephan C, Dalby K. Targeting the Oncogenic Functions of an RNA-Binding Protein Involved in Hematologic Malignancies. Blood 138 (Supp 1)(2226), 2021. e-Pub 2021.
- Post SM, Aitken MJ, Malaney PM, Zhang X, Link T, Jacamo R, Kanagal-Shamanna R, Bueso-Ramos CE. Increased hnRNP K Expression Impacts Myelopoiesis By Altering RUNX1 Splicing. Blood 138 (Supp 1)(3317), 2021. e-Pub 2021.
- Quintás-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton C, Cortes J, Kornblau SM. Proteomic Profiling of 112 Proteins in Chronic Myeloid Leukemia Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Distinct Protein Expression Signatures Associated with Advanced Phase Disease and the CD34+ Compartment. Blood 118(21):2503, 2021. e-Pub 2021.
- Post SM, Ma H, Ruvolo V, Zhang X, Yasuhiro T, Tanaka K, Kozaki R, Yoshizawa T, Cortes JE, DiNardo CD, Konopleva MY, Kornblau SM, Khoury JD, MD, Andreeff M, Ruvolo P. AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells. Blood 134 (Supp 1)(2550), 2019. e-Pub 2019.
- Post SM, Ma H, Ruvolo V, Zhang X, Yasuhiro T, Tanaka K, Kozaki R, Yoshizawa T, Cortes JE, DiNardo CD, Konopleva MY, Kornblau SM, Khoury JD, MD, Andreeff M, Ruvolo P. AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells. Blood 134(Supp 1):2550, 2019. e-Pub 2019.
- Aguilar-Garrido P, Crespo-García C, Carrasco-Rubio L, Aitken MJ, Malaney P, Zhang X, Young KY, Post SM, Martinez-Lopez J, Gallardo M. HNRNP K OVEREXPRESSION INDUCE NUCLEOLAR STRESS, A HALLMARK OF ACUTE MYELOID LEUKEMIA. EHA Library 266049(PF250), 2019. e-Pub 2019.
- Post SM, Malaney P, Young K, Gallardo M, Hornbaker M, Zhang X, Bueso-Ramos C, Martinez-Lopez J. HNRNP K LEVELS PREDICT FOR POOR CLINICAL RESPONSES IN DLBCL AND REPRESENT A NOVEL THERAPEUTIC TARGET. EHA Library 267429(S846), 2019. e-Pub 2019.
- Post SM, Malaney P, Young K, Gallardo M, Hornbaker M, Zhang X, Bueso-Ramos C, Martinez-Lopez J. S846: hnRNP K levels predict for poor clinical responses in DLBCL and represent a novel therapeutic target. Hemasphere 3(S1):377, 2019.
- Malaney P, Gallardo M, Hornbaker MJ, Zhang X Link T, Shah V, Alybayev S, Wu MH, Pageon LR, DVM, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton M, Martinez-Lopez J, Bueso-Ramos CE, Young KH, Post SM. hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis. Blood 132 (Supp 1)(1346), 2018. e-Pub 2018.
- Gu A, PhD, Ma H, Zhang X, Malaney P, Gallardo M, Liu J, Neelapu SS, Post SM. Combination Therapy with BTK Inhibitor Plus Anti-PD-1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL. Blood 132 (Supp 1)(4416), 2018. e-Pub 2018.
- Hornbaker MJ, Malaney P, Zhang X, Duan R, Shah V, Herbrich S, Gallardo M, Jacamo R, Link T, Ma H, Alybayev S, Kornblau SM, Hu P, Sarbassov D, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1. Blood 132 (Supp 1)(2622), 2018. e-Pub 2018.
- Ruvolo PP, Ma H, Ruvolo V, Zhang X, Mu H, Yasuhiro T, Tanaka K, Yoshizawa T, Zhang W, Cortes JE, Andreeff M, Post SM. TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia. Blood(132 (Supp 1)):2642, 2018. e-Pub 2018.
- Ruvolo PP, Ma H, Ruvolo V, Zhang X, Mu H, Yasuhiro T, Tanaka K, Yoshizawa T, Zhang W, Cortes JE, Andreeff M, Post SM. TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia. Blood 132(Supp 1):2642, 2018. e-Pub 2018.
- Gu A, PhD, Ma H, Zhang X, Malaney P, Gallardo M, Liu J, Neelapu SS, Post SM. Combination Therapy with BTK Inhibitor Plus Anti-PD-1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL. Blood 132(Supp 1):4416, 2018. e-Pub 2018.
- Hornbaker MJ, Malaney P, Zhang X, Duan R, Shah V, Herbrich S, Gallardo M, Jacamo R, Link T, Ma H, Alybayev S, Kornblau SM, Hu P, Sarbassov D, Kanagal-Shamanna R, Bueso-Ramos CE, Post SM. hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1. Blood 132(Supp 1):2622, 2018. e-Pub 2018.
- Malaney P, Gallardo M, Hornbaker MJ, Zhang X Link T, Shah V, Alybayev S, Wu MH, Pageon LR, DVM, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton M, Martinez-Lopez J, Bueso-Ramos CE, Young KH, Post SM. hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis. Blood 132(Supp 1):1346, 2018. e-Pub 2018.
- Hornbaker MJ, Gallardo M, Zhang X, Malaney P, Herbrich S, Ma H, Hu MP, Kornblau S, Bueso-Ramos CE, Post SM. hnRNP K: A Driver of Myeloid Malignancy. Blood 130 (Sup1)(2511), 2017. e-Pub 2017.
- Hornbaker MJ, Gallardo M, Zhang X, Malaney P, Herbrich S, Ma H, Hu MP, Kornblau S, Bueso-Ramos CE, Post SM. hnRNP K: A Driver of Myeloid Malignancy. Blood 130(Supp 1):2511, 2017. e-Pub 2017.
- Post SM, Lee HJ, Ma H, Gallardo M, Zhang X, Hornbaker M. EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53. EHA Library P590(181877), 2017. e-Pub 2017.
- Ruvolo P, Ma H, Ruvolo V, Mu H, PhD MD, Schober W, Yasuhiro T, Yoshizawa T, Gallardo M, Zhang X, Khoury JD, Cortes JE, Andreeff M, Post SM. AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells. Blood 128(22):3939, 2016. e-Pub 2016.
- Hornbaker MJ, Gallardo M, Zhang X, Ma H, Hu P, Khoury JD, Kornblau SM, Bueso-Ramos CE, Post SM. hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation. Blood 128(22):744, 2016. e-Pub 2016.
- Peter Ruvolo P, Ma H, Ruvolo V, Mu H, W, Yasuhiro T, Yoshizawa T, Gallardo M, Zhang X, Khoury KD, Cortes J, Andreeff M, Post SM. AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells. Blood 128(22):3939, 2016. e-Pub 2016.
- Hornbaker MJ, Gallardo M, Zhang X, Ma H, Hu P, Khoury JD, Kornblau SM, Bueso-Ramos CE, Post SM. Gallardo M, Lee HJ, Zhang X, Bueso-Ramos CE, Pageon L, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, P Hu, Qi Y, Su X, Rapado P, Quintás-Cardama A, Kornblau SM, Martinez-López J, Pos SM. Blood 128(22):744, 2016. e-Pub 2016.
- Peter Ruvolo P, Ma H, Ruvolo V, Mu H, W, Yasuhiro T, Yoshizawa T, Gallardo M, Zhang X, Khoury KD, Cortes J, Andreeff M, Post SM. AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells. Blood 128(22):3939, 2016. e-Pub 2016.
- Gallardo M, Hornbaker M, Zhang X, McArthur M, Manshouri T, Martinez-Lopez J, Post SM. HNRNP K: A NOVEL ONCOGENE THAT DRIVES C-MYC-DEPENDENT LYMPHOMAS AS A POTENTIAL THERAPY TARGET. EHA Library 133565(P677), 2016. e-Pub 2016.
- Gallardo M, Hornbaker M, Zhang X, McArthur M, Manshouri T, Martinez-Lopez J, Post SM. HNRNP K: A NOVEL ONCOGENE THAT DRIVES C-MYC-DEPENDENT LYMPHOMAS AS A POTENTIAL THERAPY TARGET. EHA Library P677(133565), 2016. e-Pub 2016.
- Gallardo M, Hornbaker MJ, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Manshouri T, Parker-Thornburg J, Peter Hu P, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. HNRNP K: AN ONCOGENE AND TUMOR SUPPRESSOR, TWO DISCRETE PATHS TO AML THROUGH ON GENE. EHA Library 135153(S120), 2016. e-Pub 2016.
- Gallardo M, Zhang X, McArthur M, Manshouri T, Post SM. Amplification of hnRNP K Drives c-Myc-Dependent Malignancies and Represent a Novel Therapeutic Opportunity for Hematologic Malignancies. Blood 126(23):468, 2015. e-Pub 2015.
- Gallardo M, Lee HJ, Zhang X, Bueso-Ramos CE, Pageon L, McArthur M, Multani A, Nazha A Manshouri T, Parker-Thornburg J, Hu P, Qi Y, Su X, Rapado I, Quintás-Cardama A, Kornblau SM, Martinez-López J, Post SM. hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. Blood 126(23):439, 2015. e-Pub 2015.
- Lee HJ, Gallardo M, Zhang X, Ma H, Quintas-Cardama A, Qi Y, Su X, Post SM. Developing Therapeutic Strategies for CLL with Mutant p53. Blood 126(23):2476, 2015. e-Pub 2015.
- Gallardo M, Zhang X, McArthur M, Manshouri T, Post SM. Amplification of hnRNP K Drives c-Myc-Dependent Malignancies and Represent a Novel Therapeutic Opportunity for Hematologic Malignancies. Blood 126(23):468, 2015. e-Pub 2015.
- Gallardo M, Lee HJ, Zhang X, Bueso-Ramos CE, Pageon L, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Hu P, Qi Y, Su X, Rapado P, Quintás-Cardama A, Kornblau SM, Martinez-López J, Pos SM. hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML. Blood 126(23):439, 2015. e-Pub 2015.
- Lee HJ, Gallardo M, Zhang X, Ma H, Quintas-Cardama A, Qi Y, Su X, Post SM. Developing Therapeutic Strategies for CLL with Mutant p53. Blood 126(23):2476, 2015. e-Pub 2015.
- Gallardo M, Lee HJ, Bueso-Ramos CE, Zhang X, Pageon LR, Multani A, Rapado I, Quintás-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K : A Tumor Suppressor or Oncogene?. Blood 124(21):259, 2014. e-Pub 2014.
- Gallardo M, Lee HJ, Zhang X, Pageon LR, Multani A, Reschke M, Clohessy JG, Quintás-Cardama A, Andreeff M, Kornblau SM, Pandolfi PP, Post SM. hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood 124(21):2382, 2014. e-Pub 2014.
- Gallardo M, Lee HJ, Zhang X, Pageon LR, Multani A, Reschke M, Clohessy JG, Quintás-Cardama A, Andreeff M, Kornblau SM, Pandolfi PP, Post SM. hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood 124(21):2382, 2014. e-Pub 2014.
- Gallardo M, Lee HJ, Bueso-Ramos CE, Zhang X, Pageon LR, Multani A, Rapado I, Quintás-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM. hnRNP K : A Tumor Suppressor or Oncogene?. Blood 124(21):259, 2014. e-Pub 2014.
- Larsson CA, Kojima K, Wang Y, Navin N, Gallardo M, Primo D, Rojas JL, Martinez J, Manshouri T, Lee HJ, Bradner, Ballesteros J, Post SM, Lozano G, Quintás-Cardama A. BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status. Blood 122(21):876, 2013. e-Pub 2013.
- Gallardo M, Lee HJ, Zhang X, Aziz Nazha A, Pageon LR, Kornblau SM, Quintás-Cardama A, Post SM. Blood hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia. Blood 122(21):226, 2013. e-Pub 2013.
- Quintas-Cardama A, Post SM, Kojima K, Qiu YH, Andreeff M, Bueso-Ramos CE, Kornblau SM. High p53 Protein Expression LEVEL Independent Of Mutational Status Is An Adverse Prognostic Factor For Survival In ACUTE Myeloid Leukemia. Blood 122(21):1330, 2013. e-Pub 2013.
- Bozinovic K, TManshouri T, Post SM, Zhang Y, Gallardo M, Zhang X, Verstovsek S. Altered Expression and Mutation Analysis Of Heterogeneous Nuclear Ribonucleoprotein k In Bone Marrow Of Primary Myelofibrosis Patients. Blood 122(21):5272, 2013. e-Pub 2013.
- Gallardo M, Lee HJ, Zhang X, Nazha A, Pageon LR, Kornblau SM, Alfonso Quintás-Cardama A, Post SM. hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia. Blood 122(21):226, 2013. e-Pub 2013.
- Lee HJ, Gallardo M, Zhang X, Quintas-Cardama A, Post SM. p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia. Blood 122(21):2885, 2013. e-Pub 2013.
- Bozinovic K, Manshouri T, Post SM, Zhang Y, Gallardo M, Zhang X, Verstovsek S. Altered Expression and Mutation Analysis Of Heterogeneous Nuclear Ribonucleoprotein k In Bone Marrow Of Primary Myelofibrosis Patients. Blood 122(21):5272, 2013. e-Pub 2013.
- Quintas-Cardama A, Post SM, Kojima K, Qiu YH, Andreeff M, Bueso-Ramos CE, Kornblau SM. High p53 Protein Expression LEVEL Independent Of Mutational Status Is An Adverse Prognostic Factor For Survival In ACUTE Myeloid Leukemia. Blood 122(21):1330, 2013. e-Pub 2013.
- Larsson CA, Kojima K, Wang Y, Navin N, Gallardo M, Rojas JL, Martinez RJ, Manshouri T, Lee HJ, Bradner JE, Ballesteros J, Post SM, Lozano G, Quintás-Cardama A. BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status. Blood 122(21):876, 2013. e-Pub 2013.
- Quintas-Cardama A, Zhang X, Attieh Y, Lee HJ, Qiu YH, Kornblau SM, Post S. hnRNP K: A Putative Regulator of Leukemogenesis and the p53 Pathway. Blood 120(21):774, 2012. e-Pub 2012.
- Quintas-Cardama A, Zhang X, Attieh Y, Lee HJ, Qiu YH, Kornblau SM, Post SM. hnRNP K: A Putative Regulator of Leukemogenesis and the p53 Pathway. Blood 120(21):774, 2012. e-Pub 2012.
- Quintás-Cardama A, Qiu YH, Post SM, Kornblau SM. Low Expression of the Novel Tumor Suppressor Trim62 Is An Independent Adverse Prognostic Factor for Survival In Acute Myeloid. Blood 118(21):563, 2011. e-Pub 2011.
Book Chapters
- Post SM, Kantarjian H, Quintas-Cardama A. Biology of Adult Myelocytic Leukemia and Myelodysplasia. In: The Molecular Basis of Cancer. In: The Molecular Basis of Cancer (Fourth Edition), 421-432, 2014.
- Post SM, Quintas-Cardama A, Lozano G. Regulation of p53 Activity and Associated Checkpoint Controls. In: Checkpoint Controls and Targets in Cancer Therapy, Cancer Drug Discovery and Development. In: Springer Science, 171-188, 2010.
Patient Reviews
CV information above last modified July 22, 2026